Market news

Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized basis producing an average annual return of 24.7%. Currently, Insmed has a market capitalization of $25.54 billion.

Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision date. The application seeks full approval and broader use alongside other antibiotics for Mycobacterium avium complex, or MAC, lung disease, a serious bacterial infection. ARIKAYCE currently has […]

Insmed has reported that the U.S. FDA previously accepted its supplemental New Drug Application for ARIKAYCE for MAC lung disease under Priority Review, with a target action date of January 28, 2027, based on positive Phase 3b ENCORE data fulfilling a key post-marketing requirement. The ENCORE trial results could allow ARIKAYCE to be used earlier in the MAC disease course and support label expansion discussions in Japan, potentially broadening its treatment reach while maintaining a safety...

Insmed (INSM) said Monday the US Food and Drug Administration has granted priority review to its sup

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]

Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent […]

On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year ago to just $13.2 million. The numbers tell the story of […]

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

Motley Fool Press Release.

Detailed price information for Insmed Inc (INSM-Q) from The Globe and Mail including charting and trades.

Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of $28.82 billion.

Insmed's (INSM) Q2 results and management commentary reinforced confidence in Brinsupri's commercial

Moby summary of Insmed Incorporated's Q2 2026 earnings call

Insmed stock led a biotech rally Thursday, catapulting more than 30% on solid second-quarter sales for its new lung disease drug.

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insmed (INSM) delivered earnings and revenue surprises of +24.64% and +9.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) reported a Q2 loss Thursday of $0.06 per share, narrowing from a loss of $1.70 a year